These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25233430)

  • 1. Deciphering non-alcoholic fatty liver disease through metabolomics.
    Cano A; Alonso C
    Biochem Soc Trans; 2014 Oct; 42(5):1447-52. PubMed ID: 25233430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Voiculescu M; Nanau RM; Neuman MG
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis].
    Berlanga A; Guiu-Jurado E; Porras JA; Aragonès G; Auguet T
    Clin Investig Arterioscler; 2016; 28(1):47-61. PubMed ID: 26049666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoids and non-alcoholic fatty liver disease.
    Woods CP; Hazlehurst JM; Tomlinson JW
    J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-alcoholic fatty liver disease (NAFLD) /non-alcoholic steatohepatitis (NASH) and nutrition].
    Ishii KA; Takamura T
    Clin Calcium; 2016 Mar; 26(3):363-7. PubMed ID: 26923972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Miele L; Forgione A; Gasbarrini G; Grieco A
    Transl Res; 2007 Mar; 149(3):114-25. PubMed ID: 17320797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology.
    Gnocchi D; Custodero C; Sabbà C; Mazzocca A
    J Mol Med (Berl); 2019 Jun; 97(6):741-759. PubMed ID: 30953079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
    Liu J; Wang G; Jia Y; Xu Y
    Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD.
    Fuchs CD; Claudel T; Trauner M
    Trends Endocrinol Metab; 2014 Nov; 25(11):576-85. PubMed ID: 25183341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
    Amacher DE
    Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease.
    Fisher CP; Kierzek AM; Plant NJ; Moore JB
    World J Gastroenterol; 2014 Nov; 20(41):15070-8. PubMed ID: 25386055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Lipid Species Linked to the Progression of Non-Alcoholic Fatty Liver Disease.
    Kawano Y; Nishiumi S; Saito M; Yano Y; Azuma T; Yoshida M
    Curr Drug Targets; 2015; 16(12):1293-300. PubMed ID: 25850622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology and pathophysiology of liver lipid metabolism.
    Ponziani FR; Pecere S; Gasbarrini A; Ojetti V
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1055-67. PubMed ID: 26070860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.